ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma

Luo, Jialiang; Li, Lei; Zhu, Zhengyumeng; Chang, Bo; Deng, Fan; Wang, Di; Lu, Xiao; Zuo, Daming; Chen, Qingyun*; Zhou, Jia*广东省人民医院; 南方医科大学
Biomedicine and Pharmacotherapy2022-10DOI: 10.1016/j.biopha.2022.113602
8被引5阅读
引用收藏
分享

摘要

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Although sorafenib is a standard first-line molecule-targeted drug against advanced HCC, the drug resistance development and adverse side effects usually limit its efficacy. This study investigated the effect of fucoidan on the sorafenib sensitivity of sorafenib-resistant human HCC cell line HepG2-SR established by long-time exposure of HepG2 to sorafenib. We demonstrated fucoidan combined with sorafenib synergistically promoted apoptosis and cell cycle arrest whereas inhibited cell migration in HepG2-SR cells. This combination treatment effectively suppressed the cellular epithelial growth factor receptor (EGFR) nuclear distribution and downstream gene transcription. Interestingly, fucoidan bound the cell surface EGFR, dampening EGFR translocation to lipid raft and further nuclear distribution, restoring the sorafenib sensitivity in HepG2-SR cells. Blocking fucoidan-EGFR interaction using EGFR antibody restrained the enhanced anti-tumor effects upon the combined administration. Besides, EGFR knockdown abolished the combination treatment-improved anti-tumor efficacy. This combination also suppressed in vivo xenograft tumor growth in nude mice. Our present study uncovered that fucoidan overcame sorafenib resistance in HCC via its interaction with cell membrane EGFR and further suppression of EGFR redistribution and downstream signaling in sorafenib-resistant cells. Overall, current results suggest that simultaneous treatment of fucoidan and sorafenib might serve as a potential therapeutic strategy against sorafenib-resistant HCC.

学科与关键词

关键词
FucoidanSorafenib resistanceHepatocellular carcinomaEGFR
相关
加载中…
  • FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma
    Tan, Xiang-Peng; Xiong, Ben-Han; Zhang, Yuan-Xu; Wang, Shen-Li; Zuo, Qian*; Li, Jing*European Journal of Pharmacology, 2022, 931: 175186.被引 5
  • TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib
    Wang, Zongwen; Zhu, Qiankun; Li, Xiaodong; Ren, Xiaohang; Li, Jingtao; Zhang, Yao; Zeng, Shicong; Xu, Lishan; Dong, Xiaoqun*; Zhai, Bo*American Journal of Cancer Research, 2022, 12(9): 4343-+.被引 7
  • ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma
    Huang, Wenbin; Chen, Kunling; Lu, Yishi; Zhang, Donghui; Cheng, Yuan; Li, Liuran; Huang, Weimei; He, Guolin; Liao, Hangyu; Cai, Lei; Tang, Yujun; Zhao, Liang*; Pan, MingxinNeoplasia, 2021, 23(12): 1227-1239.被引 59
查看全部 →

发表信息

论文状态
公开发表
期刊
Biomedicine and Pharmacotherapy
发表日期
2022-10
卷期
第 154 卷
页码
113602
DOI
10.1016/j.biopha.2022.113602
语言
MULTI-LANGUAGE
成果收录
SCIE
资助标注
National Natural Science Foun-dation of China [81873872, 81971550, 82171745]; Guangdong Basic and Applied Basic Research Foundation of Guangdong Province [2022A1515012437, 2022A1515012579]

作者

  • L

    Luo, Jialiang (第一作者)

    southern med univ

  • L

    Li, Lei

    southern med univ

查看全部 10 位作者收起作者
  • Z

    Zhu, Zhengyumeng

    southern med univ

  • C

    Chang, Bo

    southern med univ

  • D

    Deng, Fan

    southern med univ

  • W

    Wang, Di

    southern med univ

  • L

    Lu, Xiao

    southern med univ

  • Z

    Zuo, Daming

    southern med univ

  • C

    Chen, Qingyun (通讯)

    guangdong prov peoples hosp

  • Z

    Zhou, Jia (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417